---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349374"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-08-13T20:36:03+00:00"
generated_at: "2026-08-13T20:37:30.387868+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest Q2 net loss $5.2M; TPST-4003 collaboration with Senlang, first dosing Q4 2026

## Summary
- Q2 net loss $5.2M ($0.34/share) vs $7.9M ($2.07) year ago; cash $0.8M at June 30.
- Collaboration with Senlang Biotechnology for TPST-4003 in vivo CAR-T; first dosing expected Q4 2026, data H1 2027.
- TPST-2003 trials: 100% complete response in 15 CAR-T-naive evaluable patients; no Grade ≥3 CRS/ICANS.
- Appointed Drake Richey and John Yee to board; Andrew Fang as Head of Business Development.
- Warrant inducement raised ~$2M gross proceeds; H1 cash used in ops $10.4M.

## SEC filing metadata
- accession: 0001193125-26-349374
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-08-13T20:36:03+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/0001193125-26-349374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526349374/tpst-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349374
- JSON: https://secwatch.observer/filing/0001193125-26-349374.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.